Chime Biologics deepens collaboration with Cytiva to boost manufacturing capacity

June 8

• Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform
• Designed to support late-phase and commercial manufacturing, GMP-2 provides flexible and scalable manufacturing solutions for global biologics partners seeking accelerated commercialization and reliable global supply.
• Chime Biologics also unveiled its vision for a next-generation AI-powered Megafactory with a capacity of over 100 2,000L bioreactors.

Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, today announced the inauguration of its GMP-2 manufacturing facility in Wuhan, China, further expanding its capacity to support growing global demand for biologics. The new facility is equipped with eight 2,000-liter single-use Xcellerex bioreactors from Cytiva, a Danaher company and a leader in the life sciences industry, providing flexible and efficient capacity to support scale-up from discovery to delivery, while maintaining consistent quality.

Jimmy Wei, Board Director and CEO, Chime Biologics, says: ”From the world’s first KUBio commercial biosimilars facility in 2016 to today’s GMP-2 launch and future Megafactory vision, Cytiva has been an important strategic partner throughout our growth journey. As the global biologics industry continues evolving toward more complex and increasingly commercial-stage pipelines, we believe next-generation manufacturing platforms must combine flexible capacity, intelligent operations, and accelerated scalability to better support our global partners’ long-term success.”

This latest expansion builds on a decade of collaboration between Cytiva and Chime Biologics. The company’s first manufacturing facility was built using the KUBio modular manufacturing platform. The platform supported Chime Biologics’ growth from early-stage development to global commercial manufacturing, enabling a phased and efficient scale-up approach which aligned to customer needs.

Allen Li, President of Cytiva in China, says: “Chime Biologics’ continued expansion reflects how flexible and scalable manufacturing solutions are helping biopharma companies respond to growing global demand. At Cytiva, we remain committed to supporting our customers in China and globally with trusted technologies and consistent quality - contributing to a more resilient and increasingly diversified global biomanufacturing landscape.”

Chime Biologics also announced plans on investing in a new AI-Powered Megafactory with over 100 2,000L bioreactors, which is expected to become the single largest biologics manufacturing campus in China.

The expansion further reinforces Chime Biologics’ position as a globally-oriented CDMO, with overseas markets already accounting for approximately 50% of total order value. Following the commissioning of the new GMP-2 facility, the company expects to increase the share of revenue from markets outside China to around 70% over the next five years.

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

---

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15,000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at Cytiva.com

Cytiva is proud to be part of Danaher. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

Media contact:

Cytiva
Felix Chan | felix.chan@cytiva.com (APAC)
Mandy Ren | mandy.ren@danaher.com (China)

Chime Biologics
Leo Lyu | llyu@chimebiologics.com